Harriet Lane Handbook
- Dabigatran etexilate mesylate (Pradaxa)
- Dactinomycin
- Dandruff
- Dasatinib
- Daunorubicin
- D-dimer
- Deafness
- Death certificates
- Debridement, of burn
- Decanoate
- Decision-making tools (DMTs)
- Decompensated, shock
- Decontamination
- Deep dermal suture
- Deep sedation
- Deferoxamine mesylate (Desferal)
- Defibrillation
- Defibrotide, for sinusoidal obstructive syndrome
- Deficit repletion
- Dehydroepiandrosterone sulfate (DHEA-S)
- Delayed puberty
- Delayed sleep phase syndrome
- Delayed transfusion reaction
- Delirium, in toxicology
- Delivery room
- Delta gap, calculation of
- Dengue
- Dennie-Morgan lines
- Dentition, examination of
- Deoxycorticosterone (DCC) acetate, potency of
- Depigmentation
- Depot medroxyprogesterone acetate (DMPA, [Depo-Provera])
- Dermal melanocytosis, congenital
- Dermalon, characteristics of
- Dermatologic changes, as death approaches
- Dermatomal lesions
- Dermatomes
- Dermatomyositis, associated antibody in
- Desensitization
- Desired factor replacement, in hemophilia
- Desloratadine
- Desmopressin (DDAVP), for von Willebrand (vW) disease
- Desonide
- Desoximetasone
- Detergent pods
- Developmental delay
- Developmental history
- Developmental night waking
- Developmental quotient (QI)
- Developmental surveillance
- Deviancy
- Dexamethasone with ciprofloxacin (Ciprodex)
- Dexrazoxane
- Dextroamphetamine sulfate (Zenzedi)
- Diabetic foot infection, treatment of
- Diabetic ketoacidosis (DKA)
- Diabetic neuropathy, screening for
- Diaper dermatitis
- Diastolic sounds
- Diathesis, bleeding
- Diclofenac
- Dicloxacillin sodium (Dycill, Pathocil)
- Dientamoeba fragilis, paromomycin sulfate for
- Dietary supplementation
- Diflorasone diacetate
- Dihydrotestosterone (DHT)
- Dilated cardiomyopathy
- Dilated funduscopic examination
- Dilute Russell viper venom time (dRVVT)
- Dimercaprol (BAL), for lead poisoning
- Dimercaprol (British anti-Lewisite)
- Dinutuximab
- Direct compression, for epistaxis
- Directed donor transfusions
- Disability Programs and Services (website)
- Discharge, prior to, routine newborn care
- Discharge criteria, for procedural sedation
- Discontinuing interventions
- Disease-modifying antirheumatic drugs (DMARDS)
- Disimpaction
- Dislocation reduction, of finger/toe
- Disopyramide
- Displacement of the ETT, Obstruction, Pneumothorax, or Equipment failure (DOPE)
- Disseminated gonococcal infection
- Disseminated intravascular coagulation
- Dissociation
- Dissociative sedation
- Distal tubule, pH balance and
- Distress
- DNA cross-linker
- DNA strand breaker
- Do Not Attempt Resuscitation (DNAR) orders
- Do Not Escalate Treatment requests
- Dopamine antagonists
- Dopamine disorders
- Dopa-responsive dystonia
- Dose adjustment methods
- Double-volume exchange transfusion
- Down syndrome (Trisomy 21)
- Doxapram HCl (Dopram)
- Doxazosin
- Doxorubicin (adriamycin)
- Dravet syndrome
- Drug-induced extrapyramidal symptoms, benztropine mesylate for
- Drug-induced neuritis, pyridoxine for
- Drug-induced thrombocytopenia
- Drug intolerance
- Drugs, Infection, Metabolic, and Structural causes (DIMS)
- Duchenne muscular dystrophy (DMD)
- Duocal, calories of
- Duodenal atresia
- Dupilumab, for atopic dermatitis (eczema)
- Dysfunctional pain
- Dyskeratosis congenita
- Dyskinesias, ciliary, primary
- Dysmotility, gastrointestinal reflux disease and
- Dysphoria, gender
- Dyspigmentation
- Dysplasia, Greenberg
- Dyspnea
- Dystonia, dopa-responsive
- Dystonic reactions, diphenhydramine for